AXSM News and Press, Axsome Therapeutics Inc. From 07/23/22

There's a reason why the Rocky movies were so successful: Nearly everybody loves a comeback. That isn't just true in entertainment; investors like comeback stories, too. We asked three Motley Fool contributors to pick beaten-down stocks that they think could soar in the second half ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks bottomed in mid-June and have seen some upward momentum since then. The recovery is in line with the broader market. But the industry has yet to get a lift from fundamental improvement. Click to Enlarge ...

It's been an ugly year in the stock market in 2022, and most investors are deep in the red. But there's always a winner somewhere. Right now healthcare is seeing a lot of bright spots. For instance, Immunocore (NASDAQ: IMCR) investors just had a U.S. Food and Drug Administration...

Bitcoin and other cryptocurrencies are all the rage these days, and many investors are thinking of jumping on the bandwagon. Some Bitcoin optimists believe that it will replace fiat currency, that is, government-issued (or government-backed) currency whose value isn't linked to any comm...

Axsome Therapeutics ([[AXSM]] +0.1%) announces that it remains on track and is in the process of submitting a New Drug Application for AXS-05 in major depressive disorder to the U.S. FDA.Axsome initiated its ACCORD study, a Phase 3, randomized, double-blind, placebo-controlled trial...

Axsome Therapeutics (NASDAQ: AXSM) was a penny stock at the end of 2018. Shares dropped all the way to $1.94 on Dec. 27. If you invested $20,000 in Axsome on that day, you'd have 10,309 shares. And if you held on to those shares, a year later you would have been a millionaire. Y...

Myovant Sciences (MYOV) appointed David Marek as chief executive officer to succeed Lynn Seely, M.D.Mr. Marek will also serve as principal executive officer of Myovant Sciences Ltd. and as a member of its board. Marek is a veteran biopharmaceutical executive with...

Axsome Therapeutics (AXSM) initiates ACCORD (Assessing Clinical Outcomes in Alzheimer’s Disease Agitation) study, a Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of AXS-05 in the treatment of Alzheimer’s disease agitation. AXS-05...

ACCORD is the second pivotal trial of AXS-05 in Alzheimer’s disease agitation No treatments are currently approved for Alzheimer’s disease agitation NEW YORK, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical compan...

Over 21,000 migraine attacks treated with AXS-07 Achieved migraine pain relief in approximately 70% of patients, and pain freedom in approximately 40% of patients, at 2 hours Achieved durable relief, with approximately 85% of patients free from rescue medication use over 4...